SEO URLwww.firestrike.ai/deals/perfuse-therapeutics-bayer-acquisition-2026-1
acquisitionAnnounced · May 6, 2026ophthalmologySource · CredibleArticle · Factual
Bayer acquires Perfuse Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
—
Target
Perfuse Therapeutics
San Francisco, California
Acquirer
Bayer
Full Acquisition
Status
Announced
Bayer agreed to acquire Perfuse Therapeutics. Reported deal value: Undisclosed. Status: Announced. Sector: ophthalmology. Target headquarters context: San Francisco, California, United States.
This page summarizes publicly available information about the transaction as of 2026-05-06. Figures and status may change as filings and press coverage update.
SHOW MORE Madrigal and Bayer strike billion -dollar deals to expand pipelines, with Madrigal licensing a PNPLA3 -targeting siRNA for MASH and Bayer acquiring Perfuse Therapeutics to strengthen its ophthalmology portfolio
Deal timeline
Announced
May 6, 2026 · pharmexec.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in ophthalmology. Figures and status may change as sources update.
Sources: pharmexec.com · Primary article · FireStrike proprietary index